| 1 |
34915026 | Dependence of ABCB1 transporter expression and function on distinct sphingolipids generated by ceramide synthases-2 and -6 in chemoresistant renal cancer. | 2022 Feb |
1 |
| 2 |
33668794 | The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. | 2021 Feb 25 |
1 |
| 3 |
33860196 | Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells. | 2021 Apr 9 |
1 |
| 4 |
30365089 | Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1. | 2019 Jan |
1 |
| 5 |
29766327 | Characterization of carfilzomib-resistant non-small cell lung cancer cell lines. | 2018 Jul |
1 |
| 6 |
30441975 | Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients. | Spring 2018 |
1 |
| 7 |
27813130 | P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors. | 2017 May |
1 |
| 8 |
28000886 | hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. | 2017 Feb |
2 |
| 9 |
28509582 | Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. | 2017 Dec |
2 |
| 10 |
25477008 | Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. | 2015 Feb |
1 |
| 11 |
25576094 | Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function. | 2015 Feb 15 |
4 |
| 12 |
25590413 | Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells. | 2015 |
1 |
| 13 |
24899604 | Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib. | 2014 |
4 |
| 14 |
25216523 | Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. | 2014 Aug 30 |
2 |
| 15 |
23589314 | The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. | 2013 May |
10 |
| 16 |
22145750 | Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines. | 2012 Jun |
3 |
| 17 |
22235146 | Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. | 2012 Apr |
1 |
| 18 |
22512091 | The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. | 2012 Feb |
5 |
| 19 |
22082269 | Influence of proteasome inhibitor bortezomib on the expression of multidrug resistance genes and Akt kinase activity. | 2011 Sep |
3 |
| 20 |
19254348 | The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02. | 2010 Feb |
3 |
| 21 |
20532504 | Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. | 2010 Nov |
5 |
| 22 |
17096161 | Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. | 2007 Jul |
2 |
| 23 |
17662692 | Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. | 2007 Sep 21 |
5 |